Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2

INTRODUCTION: New open-angle glaucoma (OAG) and ocular hypertension (OHT) therapies that reduce treatment burden and improve outcomes relative to currently available agents are needed. Netarsudil, a novel Rho kinase inhibitor approved by the US Food and Drug Administration, reduces intraocular press...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Adv Ther
Autors principals: Asrani, Sanjay, Bacharach, Jason, Holland, Edward, McKee, Hayley, Sheng, Huan, Lewis, Richard A., Kopczynski, Casey C., Heah, Theresa
Format: Artigo
Idioma:Inglês
Publicat: Springer Healthcare 2020
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7140751/
https://ncbi.nlm.nih.gov/pubmed/32166538
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-020-01277-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars